Tzvia Bader and TrialJectory
Tzvia Bader is the CEO and Co-Founder of TrialJectory. She is an experienced entrepreneur with decades of experience in business development, product marketing and strategy. Prior to TrialJectory, Tzvia headed the global business unit at Amdoc building new product strategy. She was the founder and CEO of KIDDOapp, and IOS and Android based family scheduling technology strategy and Vocativ, a start-up aiming to identify fake news in social media using advanced analytics. Tzvia holds a Msc (Masters of Science) degree from the University of Nottingham, Nottingham,UK.
TrialJectory – Matching Cancer Patients to Clinical Trials
With a diagnosis of malignant melanoma in hand, for Tzvia Bader this was not a battle that she could lose. Having been a technology executive for many years, she did what she knew best and turned to the internet. In her mind she had pictured a scenario similar to searching for a new house, like Zillow. Tzvia quickly discovered that this did not exist.
Tzvia learned that the process for patients to gain access to advanced treatments through clinical trials was completely broken. She mentioned this to her husband. His response: build one. And so Tzvia went about building TrialJectory. TrialJectory is democratizing access to advanced cancer treatment. Tzvia built an AI-Powered decision support platform empowering patients to own their own cancer journey. The Artificial Intelligence (AI) system helps patients understand all treatment options. In addition, it gives pharmaceutical companies transparency into patients’ needs and wants. And allows them to effectively design and recruit for clinical trials.
A very informative and hopeful conversation with Tzvia:
The cancer diagnosis and one oncologist
‘Zillow’ like search and the broken findings
A caring oncologist and his limitations
Clinical trials making choices
Owning your journey
Breaking through the boundaries of fear
The formation of TrialJectory
Opening doors for patients
Research, technology and access to real data
Access and cost of clinical trials – it’s not what you think